Pharmaceutical composition and methods of uses

Abstract

The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12.

What is claimed is: 
     
         1 . A pharmaceutical composition comprising an amorphous compound of formula (I) or a salt thereof or a hydrate of the foregoing, and a cyclodextrin, wherein R is selected from the group consisting of phenyl, 4-benzyloxyphenyl, 4-biphenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2-methoxyphenyl, 3,5-dimethoxyphenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, and 3-trifluoromethylphenyl. 
       
         
           
           
               
               
           
         
       
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the weight ratio of the compound of formula (I) to the cyclodextrin is from 1:1 to 1:50. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition increases the solubility of the compound of formula (I) in deionized water at room temperature, by at least 1.5-fold compared to the solubility of the compound of formula (I) without the cyclodextrin under the same conditions. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition increases the oral bioavailability of the compound of formula (I) in a mammal by at least 50% over the oral bioavailability of the compound of formula (I) without cyclodextrin. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition induces at least 2-times greater Cmax of the compound of formula (I) than Cmax of the compound of formula (I) when the compound is administered alone in the same amount and under the same conditions. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the cyclodextrin is a water soluble unsubstituted or substituted alpha-cyclodextrin, beta-cyclodextrin, or gamma-cyclodextrin. 
     
     
         7 . The pharmaceutical composition of  claim 6 , wherein the beta-cyclodextrin is selected from the group consisting of methyl beta-cyclodextrin, hydroxypropyl beta-cyclodextrin, and sulfobutylether beta-cyclodextrin. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein at least a moiety of the compound of the formula (I) has inserted itself, at least partially, into the cavity of the cyclodextrin.